189 related articles for article (PubMed ID: 25701036)
1. Multifunctional porous silicon nanoparticles for cancer theranostics.
Wang CF; Sarparanta MP; Mäkilä EM; Hyvönen ML; Laakkonen PM; Salonen JJ; Hirvonen JT; Airaksinen AJ; Santos HA
Biomaterials; 2015 Apr; 48():108-18. PubMed ID: 25701036
[TBL] [Abstract][Full Text] [Related]
2. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.
Wang CF; Mäkilä EM; Kaasalainen MH; Liu D; Sarparanta MP; Airaksinen AJ; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Jan; 35(4):1257-66. PubMed ID: 24211082
[TBL] [Abstract][Full Text] [Related]
3. Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy.
Wang CF; Mäkilä EM; Kaasalainen MH; Hagström MV; Salonen JJ; Hirvonen JT; Santos HA
Acta Biomater; 2015 Apr; 16():206-14. PubMed ID: 25637067
[TBL] [Abstract][Full Text] [Related]
4. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.
Mieszawska AJ; Kim Y; Gianella A; van Rooy I; Priem B; Labarre MP; Ozcan C; Cormode DP; Petrov A; Langer R; Farokhzad OC; Fayad ZA; Mulder WJ
Bioconjug Chem; 2013 Sep; 24(9):1429-34. PubMed ID: 23957728
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells.
Correia A; Shahbazi MA; Mäkilä E; Almeida S; Salonen J; Hirvonen J; Santos HA
ACS Appl Mater Interfaces; 2015 Oct; 7(41):23197-204. PubMed ID: 26440739
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
9. Protease-targeting peptide-functionalized porous silicon nanoparticles for cancer fluorescence imaging.
Kanathasan JS; Palanisamy UD; Radhakrishnan AK; Chakravarthi S; Thong TB; Swamy V
Nanomedicine (Lond); 2022 Sep; 17(21):1511-1528. PubMed ID: 36382634
[No Abstract] [Full Text] [Related]
10. Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics.
Liu Z; Li Y; Li W; Xiao C; Liu D; Dong C; Zhang M; Mäkilä E; Kemell M; Salonen J; Hirvonen JT; Zhang H; Zhou D; Deng X; Santos HA
Adv Mater; 2018 Jun; 30(24):e1703393. PubMed ID: 29024054
[TBL] [Abstract][Full Text] [Related]
11. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
12. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
[No Abstract] [Full Text] [Related]
13. Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles.
Shahbazi MA; Almeida PV; Correia A; Herranz-Blanco B; Shrestha N; Mäkilä E; Salonen J; Hirvonen J; Santos HA
J Control Release; 2017 Mar; 249():111-122. PubMed ID: 28159519
[TBL] [Abstract][Full Text] [Related]
14. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
17. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
18. All-in-One Nanomedicine: Multifunctional Single-Component Nanoparticles for Cancer Theranostics.
Cai Y; Chen X; Si J; Mou X; Dong X
Small; 2021 Dec; 17(52):e2103072. PubMed ID: 34561968
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
20. Preparation and in vivo evaluation of red blood cell membrane coated porous silicon nanoparticles implanted with
Jakobsson U; Mäkilä E; Rahikkala A; Imlimthan S; Lampuoti J; Ranjan S; Heino J; Jalkanen P; Köster U; Mizohata K; Santos HA; Salonen J; Airaksinen AJ; Sarparanta M; Helariutta K
Nucl Med Biol; 2020; 84-85():102-110. PubMed ID: 32334356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
